肿瘤代谢与营养电子杂志
腫瘤代謝與營養電子雜誌
종류대사여영양전자잡지
Electronic Jourmal of Metabolism and Nutrition of Cancer
2015年
1期
39-41
,共3页
赖晓嵘%黎莹%杨冬阳%刘建化%江韦韦%马冬
賴曉嶸%黎瑩%楊鼕暘%劉建化%江韋韋%馬鼕
뢰효영%려형%양동양%류건화%강위위%마동
红细胞生成素%肿瘤%贫血%消化道
紅細胞生成素%腫瘤%貧血%消化道
홍세포생성소%종류%빈혈%소화도
Erythropoietin%Cancer%Anemia%Digestive tracts
目的:探讨消化道恶性肿瘤患者血清红细胞生成素(EPO)水平的变化,分析EPO与贫血和临床病理特征的关系。方法用化学免疫发光法检测226例1293人次的消化道恶性肿瘤患者血清EPO水平,分析EPO与临床病理特征的相关性。结果消化道肿瘤患者红细胞平均血红蛋白浓度(MCHC)为(0.29±0.01)g/L,EPO水平为(52.25±129.64)IU/L。贫血和不贫血的肿瘤患者EPO有显著性差异(Z=-27.80,P<0.05,双侧)。不同程度贫血患者的EPO有显著性差异(X=126.26, P<0.01,双侧)。IV期患者和其他分期患者E P O水平分别为(60.05±141.43)IU/L和(21.80±28.69)IU/L,有显著性差异(X=52.47,P<0.01,双侧),血红蛋白浓度分别为(122.24±19.66)g/L和(130.98±16.95)g/L,有显著性差异(X=47.87, P<0.01,双侧)。消化道肿瘤患者化疗前后患者贫血程度及EPO水平无显著性差异。结论消化道恶性肿瘤贫血多为小细胞低色素性贫血。贫血肿瘤患者血清EPO水平异常增高,且肿瘤晚期和转移患者EPO水平增高更明显。分析化疗和贫血及EPO的关系还需要考虑更多相关因素。
目的:探討消化道噁性腫瘤患者血清紅細胞生成素(EPO)水平的變化,分析EPO與貧血和臨床病理特徵的關繫。方法用化學免疫髮光法檢測226例1293人次的消化道噁性腫瘤患者血清EPO水平,分析EPO與臨床病理特徵的相關性。結果消化道腫瘤患者紅細胞平均血紅蛋白濃度(MCHC)為(0.29±0.01)g/L,EPO水平為(52.25±129.64)IU/L。貧血和不貧血的腫瘤患者EPO有顯著性差異(Z=-27.80,P<0.05,雙側)。不同程度貧血患者的EPO有顯著性差異(X=126.26, P<0.01,雙側)。IV期患者和其他分期患者E P O水平分彆為(60.05±141.43)IU/L和(21.80±28.69)IU/L,有顯著性差異(X=52.47,P<0.01,雙側),血紅蛋白濃度分彆為(122.24±19.66)g/L和(130.98±16.95)g/L,有顯著性差異(X=47.87, P<0.01,雙側)。消化道腫瘤患者化療前後患者貧血程度及EPO水平無顯著性差異。結論消化道噁性腫瘤貧血多為小細胞低色素性貧血。貧血腫瘤患者血清EPO水平異常增高,且腫瘤晚期和轉移患者EPO水平增高更明顯。分析化療和貧血及EPO的關繫還需要攷慮更多相關因素。
목적:탐토소화도악성종류환자혈청홍세포생성소(EPO)수평적변화,분석EPO여빈혈화림상병리특정적관계。방법용화학면역발광법검측226례1293인차적소화도악성종류환자혈청EPO수평,분석EPO여림상병리특정적상관성。결과소화도종류환자홍세포평균혈홍단백농도(MCHC)위(0.29±0.01)g/L,EPO수평위(52.25±129.64)IU/L。빈혈화불빈혈적종류환자EPO유현저성차이(Z=-27.80,P<0.05,쌍측)。불동정도빈혈환자적EPO유현저성차이(X=126.26, P<0.01,쌍측)。IV기환자화기타분기환자E P O수평분별위(60.05±141.43)IU/L화(21.80±28.69)IU/L,유현저성차이(X=52.47,P<0.01,쌍측),혈홍단백농도분별위(122.24±19.66)g/L화(130.98±16.95)g/L,유현저성차이(X=47.87, P<0.01,쌍측)。소화도종류환자화료전후환자빈혈정도급EPO수평무현저성차이。결론소화도악성종류빈혈다위소세포저색소성빈혈。빈혈종류환자혈청EPO수평이상증고,차종류만기화전이환자EPO수평증고경명현。분석화료화빈혈급EPO적관계환수요고필경다상관인소。
Objective To investigate the clinical values of erythropoietin (EPO) in the patients with digestive tracts cancer in Guangdong General hospital. Methods 226 cases of digestive tracts cancer were analyzed, retrospectively. Results There are signiifcant differences of EPO between the groups with and without anemia in patients with digestive tracts cancers, while these patients with different degrees of anemia showed signiifcant differences in levels of EPO. Conclusions The EPO in patients with IV stage and metastasis usually had higher levels than that of earlier stage and without metastasis.